Trust Signals
- Written by the FormBlends Medical Team with primary sources from peer-reviewed journals, FDA drug labels, and published Phase 3 clinical trials.
- Every quantitative claim is tied to a named source or clearly marked as a qualitative estimate.
- No commercial relationship with Novo Nordisk (Ozempic manufacturer) or any compounding pharmacy.
- Page reviewed against FDA-approved prescribing information current as of 2025.
- Evidence grades assigned using standard hierarchy (RCT, cohort, animal, mechanism only).
Key Takeaways
- Ozempic is semaglutide, a synthetic 31-amino-acid GLP-1 receptor agonist peptide with a molecular weight of approximately 4,113.6 daltons.
- Two structural modifications, an Aib substitution at position 8 and a C18 fatty diacid chain at position 26, extend its half-life from roughly 1 to 2 minutes (native GLP-1) to approximately 7 days.
- The STEP 1 RCT (n=1,961, Wilding et al., NEJM 2021) showed mean weight loss of approximately 14.9% at 2.4 mg weekly over 68 weeks, the strongest human evidence for any non-surgical weight intervention at that time.
- Ozempic (diabetes indication) and Wegovy (obesity indication) are the same peptide molecule at different approved doses.
- Compounded semaglutide faced significant legal and regulatory restriction in the U.S. after the FDA removed semaglutide from the drug shortage list in 2025; purity concerns in independent lab testing remain documented.
What Peptide Is Ozempic? (Direct Answer)
Table of Contents
- What class of drug is Ozempic?
- What is the exact structure and sequence of semaglutide?
- How does semaglutide work, with specific numbers?
- What does the evidence actually show? (Evidence Ledger)
- What do most pages get wrong about Ozempic being a peptide?
- What is the difference between Ozempic and Wegovy?
- How does semaglutide compare to other GLP-1 peptides?
- How should semaglutide be stored, and why does chemistry matter?
- Can you get semaglutide as a compounded peptide?
- How do you read a semaglutide product label or COA?
- Frequently Asked Questions
- Sources
What Class of Drug Is Ozempic?
Ozempic belongs to the GLP-1 receptor agonist (GLP-1 RA) drug class, a subset of incretin mimetics. The FDA approved it in December 2017 for the treatment of type 2 diabetes mellitus in adults, and later added a cardiovascular risk reduction indication based on the SUSTAIN-6 trial. The active molecule, semaglutide, is also the basis of Wegovy (weight management, approved 2021) and Rybelsus (oral tablet formulation, approved 2019).
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Calling it simply a "peptide" is accurate but incomplete. Semaglutide is a lipidated peptide, meaning it carries an attached fatty acid chain, which changes its pharmacokinetics dramatically and puts it in a different pharmacological category from shorter-acting GLP-1 RAs like exenatide.
What Is the Exact Structure and Sequence of Semaglutide?
Semaglutide's backbone is based on human GLP-1(7-37), a 31-amino-acid fragment of the proglucagon gene product. Two key modifications distinguish it from the native hormone:
- Position 8 substitution: Alanine is replaced with alpha-aminoisobutyric acid (Aib), a non-proteinogenic amino acid. This single change blocks the enzyme dipeptidyl peptidase-4 (DPP-4) from cleaving the peptide at the N-terminus, the primary route of native GLP-1 degradation.
- Position 26 modification: Arginine at position 34 is replaced by lysine (to create an attachment point), and a C18 fatty diacid chain is connected to lysine-26 via a mini-PEG linker and a gamma-glutamic acid spacer. This chain allows reversible, non-covalent binding to serum albumin.
The result is a molecule with the molecular formula C187H291N45O59 and a molecular weight of approximately 4,113.6 daltons. Novo Nordisk's published regulatory submissions and peer-reviewed pharmacology papers (Lau et al., 2015, Journal of Medicinal Chemistry) describe this structure in detail.
Semaglutide shares approximately 94% amino acid sequence identity with native human GLP-1. The remaining differences are the two modifications above.
How Does Semaglutide Work? Mechanism With Specific Numbers
Semaglutide binds to the GLP-1 receptor (GLP1R), a class B G-protein-coupled receptor, and activates it with high potency. The downstream effects occur across at least three organ systems:
Pancreas (primary glucose control): GLP1R activation in pancreatic beta cells increases cyclic AMP (cAMP) via Gs-protein coupling, potentiating glucose-dependent insulin secretion. Critically, this effect is glucose-dependent: at normal or low blood glucose, the insulin-releasing signal is weak, reducing hypoglycemia risk compared to sulfonylureas. Glucagon secretion from alpha cells is also suppressed in a glucose-dependent manner.
Gastrointestinal tract: Semaglutide slows gastric emptying, which blunts postprandial glucose excursions and contributes to satiety. This effect partially diminishes over the first few weeks of treatment, a finding noted in pharmacodynamic studies by Nauck et al. and reflected in the GI side effect profile being heaviest early in the dose-escalation period.
Central nervous system: GLP-1 receptors are expressed in hypothalamic regions including the arcuate nucleus. Semaglutide's ability to cross the blood-brain barrier (likely via circumventricular organs) enables appetite suppression independent of gut effects. Preclinical data from rodent studies and human neuroimaging studies (van Bloemendaal et al., 2014) support CNS activity, though the exact contribution of central vs. peripheral GLP1R activation to clinical weight loss in humans remains an area of active research. This mechanistic detail does not prove any specific weight loss outcome by itself.
Half-life detail: Native GLP-1 has a plasma half-life of 1 to 2 minutes. Exenatide (Byetta), an earlier GLP-1 RA, has a half-life of roughly 2.4 hours. Semaglutide's albumin binding and DPP-4 resistance extend its half-life to approximately 165 to 184 hours (about 7 days), enabling once-weekly subcutaneous dosing. These figures come from Novo Nordisk's published clinical pharmacology data submitted to the FDA.
What Does the Evidence Actually Show? Evidence Ledger
| Claim | Best Evidence Type | Key Source / Trial | Effect Direction | Confidence |
|---|---|---|---|---|
| Semaglutide 1 mg weekly reduces HbA1c in type 2 diabetes | Multiple Phase 3 RCTs (SUSTAIN program) | SUSTAIN-1 through SUSTAIN-7, Marso et al., NEJM 2016 | Strong reduction (approx. 1.4% to 1.8% HbA1c decrease) | High |
| Semaglutide 2.4 mg weekly reduces body weight in adults with obesity | Phase 3 RCT | STEP 1, Wilding et al., NEJM 2021 (n=1,961) | Mean 14.9% body weight reduction vs. 2.4% placebo at 68 weeks | High |
| Semaglutide reduces major adverse cardiovascular events (MACE) | Phase 3 RCT (cardiovascular outcomes trial) | SUSTAIN-6, Marso et al., NEJM 2016 (n=3,297) | 26% relative risk reduction in 3-point MACE | High (for T2D population) |
| SELECT trial: CV benefit in non-diabetic obese adults | Phase 3 RCT | Lincoff et al., NEJM 2023 (n=17,604) | 20% relative risk reduction in MACE vs. placebo | High |
| Thyroid C-cell tumor risk | Rodent carcinogenicity studies (mechanism: C-cell GLP1R activation) | FDA prescribing information, Novo Nordisk carcinogenicity data | Observed in rodents; human relevance uncertain | Very Low for human extrapolation |
| CNS appetite suppression via hypothalamic GLP1R | Rodent studies, human neuroimaging | van Bloemendaal et al., 2014; preclinical literature | Plausible mechanistic contribution; magnitude in humans not isolated | Moderate (mechanism), Low (quantified human contribution) |
| Oral semaglutide (Rybelsus) is bioequivalent to injected | PK studies, Phase 3 RCTs (PIONEER program) | PIONEER trials; Davies et al., Lancet 2019 | Effective but oral bioavailability is approximately 1% (absorption enhancer SNAC required) | High for efficacy; High for lower bioavailability than injection |
What Do Most Pages Get Wrong About Ozempic Being a Peptide?
Most articles stop at "semaglutide is a GLP-1 peptide" and skip the details that actually matter for anyone trying to understand the drug or evaluate compounded versions.
1. The peptide label implies fragility that is not the full picture. People assume all peptides degrade rapidly. Semaglutide's albumin-binding fatty chain is specifically engineered to prevent this. In solution at proper refrigerator temperatures, an opened Ozempic pen is stable for up to 56 days per Novo Nordisk's validated stability data. That said, semaglutide is still susceptible to aggregation, oxidation at methionine residues, and hydrolysis under high-temperature or freeze-thaw conditions.
2. Sequence homology is not pharmacological equivalence. Semaglutide is 94% homologous to native GLP-1, but that 6% difference is what makes the drug work clinically. The Aib substitution and lipidation are not cosmetic changes; they are the entire pharmacokinetic strategy. A compounded product with any deviation in the fatty acid chain attachment or the Aib substitution will not be pharmacologically equivalent, even if the amino acid backbone is correct.
3. Oral bioavailability is approximately 1%. Rybelsus (oral semaglutide) uses an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) to transiently increase local gastric pH and enable transcellular absorption. Even then, absolute bioavailability is roughly 1% compared to subcutaneous injection. This is not a failure; it was deliberately designed this way, but it means oral semaglutide doses (3 mg, 7 mg, 14 mg) are far higher in milligrams than injectable doses to achieve therapeutic plasma levels.
4. The "peptide" framing leads researchers to confuse it with research peptides. Semaglutide is an FDA-approved drug, not a research peptide. Purchasing it outside a licensed pharmacy or prescription system carries legal, safety, and purity risks that are categorically different from approved product.
What Is the Difference Between Ozempic and Wegovy?
The active molecule is identical. The difference is dose, titration schedule, device, and approved indication.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved doses | 0.5 mg, 1 mg, 2 mg weekly | Up to 2.4 mg weekly |
| Approved indication | Type 2 diabetes; CV risk reduction | Chronic weight management (BMI criteria) |
| Titration schedule | Start 0.25 mg x 4 weeks, then 0.5 mg | Longer escalation over 16 to 20 weeks to 2.4 mg |
| Approval year | December 2017 | June 2021 |
How Does Semaglutide Compare to Other GLP-1 Peptides?
| Peptide / Drug | Half-life | Dosing | Mean Weight Loss (obesity trials) | Where Semaglutide Wins | Where Semaglutide Loses |
|---|---|---|---|---|---|
| Semaglutide (Ozempic / Wegovy) | Approx. 7 days | Once weekly SC | Approx. 14.9% (STEP 1) | Efficacy, once-weekly convenience, CV outcomes data | Cost, GI side effects, supply constraints |
| Liraglutide (Saxenda / Victoza) | Approx. 13 hours | Once daily SC | Approx. 8% (SCALE trial) | Longer track record, more real-world data | Lower efficacy, daily injection burden |
| Tirzepatide (Mounjaro / Zepbound) | Approx. 5 days | Once weekly SC | Approx. 20.9% at 15 mg (SURMOUNT-1) | Higher mean weight loss (dual GIP/GLP-1 agonism) | Newer drug, less long-term CV outcomes data than semaglutide |
| Exenatide (Byetta / Bydureon) | 2.4 hours (IR); approx. 2 weeks depot (ER) | Twice daily (IR); once weekly (ER) | Approx. 2 to 4 kg in diabetes trials | Lower cost in some markets, established generic pathway | Lower efficacy, more injection burden (IR form) |
| Dulaglutide (Trulicity) | Approx. 5 days | Once weekly SC | Modest (not primarily approved for weight) | Needle-free auto-injector device | Lower weight loss efficacy than semaglutide |
The honest conclusion: tirzepatide currently shows higher mean weight loss in head-to-head trial data, though it lacks semaglutide's breadth of long-term cardiovascular outcomes evidence. Semaglutide remains the best-evidenced GLP-1 RA for CV risk reduction in its drug class as of 2025.
How Should Semaglutide Be Stored, and Why Does the Chemistry Matter?
The FDA-approved Ozempic prescribing information specifies: store unused pens at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). After first use, pens may be stored at room temperature up to 86 degrees Fahrenheit (30 degrees Celsius) or refrigerated, for up to 56 days. Never freeze. Protect from light.
Why the temperature rule exists (the chemistry): Semaglutide is vulnerable to two primary degradation pathways. First, heat accelerates peptide bond hydrolysis, breaking the chain at the most labile amide linkages and destroying GLP1R binding activity. Second, the fatty diacid chain attached at lysine-26 can undergo oxidation at its double bond under prolonged UV exposure or at elevated temperatures. Albumin binding depends on this chain being intact; if it degrades, the half-life advantage disappears and the molecule clears rapidly. A degraded semaglutide solution may look identical to a viable one, which is why visual inspection is unreliable as a quality check.
Freeze-thaw: Freezing semaglutide solution risks ice crystal formation that disrupts the protein's tertiary conformation and can cause aggregation. Aggregated peptide can still be immunogenic even when pharmacologically inert, a risk that has been documented for biologic drugs generally.
Can You Get Semaglutide as a Compounded Peptide?
During the period semaglutide appeared on the FDA shortage list, 503A compounding pharmacies (serving individual patients with prescriptions) and 503B outsourcing facilities were permitted to compound semaglutide. Independent laboratory testing conducted during this period, including analyses published by industry watchdog organizations, found variable results: some compounded products matched labeled potency, while others contained impurities or off-spec concentrations.
Key concerns with any compounded semaglutide:
- Acetate vs. free-base salt: Some compounded versions used semaglutide acetate rather than the sodium salt used in approved products. The clinical significance of this difference is not fully characterized in published literature.
- No head-to-head bioequivalence data: Compounded semaglutide has not been required to demonstrate bioequivalence to Ozempic or Wegovy in human pharmacokinetic studies. This is a meaningful evidence gap, not a minor technicality.
- Tirzepatide misinformation risk: Some products marketed online as "semaglutide" have been flagged for containing different peptides or incorrect concentrations. A certificate of analysis (COA) from an independent third-party lab, not the manufacturer, is the minimum credible check.
How Do You Read a Semaglutide Product Label or COA?
Whether evaluating an approved pen or a compounded vial, here is what to verify:
| What to Check | What to Look For | Red Flag |
|---|---|---|
| Active ingredient name | "Semaglutide" (INN); molecular weight approx. 4,113 Da stated or implied | "Semaglutide acetate" without disclosure; generic names without MW confirmation |
| Concentration | Ozempic: 2 mg/1.5 mL pen; Wegovy: 2.4 mg/0.75 mL pen | Unlabeled concentration; inconsistent units (mg vs. mcg vs. IU) |
| Purity on COA | Greater than 98% purity by HPLC for compounded product | No HPLC data; purity stated without method; COA from same entity as seller |
| Sterility testing | USP sterility or endotoxin (LAL) testing for injectable products | No sterility data; "sterile filtered" without test confirmation |
| Expiration / beyond-use date | Consistent with storage conditions; not open-ended | No expiration; "stable indefinitely at room temperature" |
| NDC number (approved product) | Present for Ozempic / Wegovy; verifiable on FDA's NDC database | No NDC or NDC that does not match FDA database |
Frequently Asked Questions
What peptide is Ozempic?
Ozempic is semaglutide, a 31-amino-acid synthetic peptide that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It shares roughly 94% sequence homology with native human GLP-1 but has been chemically modified to extend its half-life to approximately 7 days.
Is semaglutide a natural or synthetic peptide?
Semaglutide is a synthetic analogue of native human GLP-1. It is not found in nature. It is produced by recombinant DNA technology in yeast and then chemically modified with a fatty diacid chain attached to lysine at position 26 to enable albumin binding and prolonged half-life.
How is semaglutide different from native GLP-1?
Native GLP-1 has a plasma half-life of 1 to 2 minutes due to rapid degradation by DPP-4. Semaglutide substitutes alanine with Aib at position 8, blocking DPP-4 cleavage, and adds a C18 fatty diacid chain via a linker at lysine-26, enabling albumin binding that extends half-life to roughly 7 days.
What class of drug is Ozempic?
Ozempic belongs to the GLP-1 receptor agonist drug class. It is a peptide-based incretin mimetic. The FDA approved it for type 2 diabetes in December 2017. The same molecule at 2.4 mg weekly is FDA-approved as Wegovy for chronic weight management.
How many amino acids does semaglutide have?
Semaglutide is a 31-amino-acid peptide. Its molecular formula is C187H291N45O59 and its molecular weight is approximately 4,113.6 daltons. The sequence is based on human GLP-1(7-37) with two key substitutions and a fatty acid side chain.
Does Ozempic work by releasing insulin?
Semaglutide stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it triggers significant insulin release only when blood glucose is elevated. It also suppresses glucagon, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite.
Is Ozempic a peptide or a protein?
Semaglutide is classified as a peptide. At 31 amino acids and approximately 4,114 daltons, it is well below the conventional protein threshold of roughly 50 amino acids or greater. However, its fatty acid modification gives it pharmacokinetics more typical of larger biologic molecules.
What is the difference between Ozempic and Wegovy?
Both are semaglutide. The difference is approved dose and indication. Ozempic is dosed at 0.5 mg, 1 mg, or 2 mg once weekly for type 2 diabetes. Wegovy is dosed at up to 2.4 mg once weekly and is FDA-approved for chronic weight management.
Can you get semaglutide as a compounded peptide?
During FDA-declared shortage periods, compounding pharmacies were permitted to produce semaglutide. The FDA removed semaglutide from the shortage list in 2025, significantly restricting compounding. Compounded versions are not FDA-approved and have shown variable purity in independent testing.
What evidence supports semaglutide for weight loss?
The STEP 1 trial (Wilding et al., NEJM 2021, n=1,961) found mean body weight reduction of approximately 14.9% over 68 weeks with 2.4 mg weekly semaglutide versus 2.4% with placebo. This is among the strongest non-surgical weight loss evidence from a large Phase 3 RCT.
What are the main side effects of semaglutide?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In STEP 1, nausea occurred in roughly 44% of the s
Related peptide guides
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For What Peptide Is Ozempic? | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight
Supports head-to-head context when pages compare older and newer GLP-1 options.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition
Supports body-composition, lean-mass, and metabolic-risk context.
PubMed
GLP-1 decision path
Use this page to decide if a provider review is the right next step
Direct answer
What Peptide Is Ozempic? research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.
Evidence check
The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.
Safety check
A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.
Next step
When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for What Peptide Is Ozempic?
This update makes What Peptide Is Ozempic? more specific by tying semaglutide, tirzepatide, cash-pay pricing, safety signals, peptides, faq to the page's original clinical, cost, access, or comparison angle.
The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable peptide therapy summary.
For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.
Custom 2026 image for What Peptide Is Ozempic?, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by the FormBlends Medical Team with primary sources from peer-reviewed journals, FDA drug labels, and published Phase 3 clinical trials.
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.